EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative Analysis of T‐Cell and Bone Marrow Chimerism for Relapse Prediction in Acute Leukaemia Post‐Transplantation

Chunfeng Li, Tongyuan Liu iD, Ying Wan, Hanwen Mao, Xiaofan Zhang, Fankai Meng iD, Jia Wei iD, Yicheng Zhang, Liting Chen, Lijun Jiang, Lifang Huang iD

HLA · 2026

DOI: 10.1111/tan.70588 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift HLA, 2026. Verfasst von Chunfeng Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, T-Lymphocytes, Hematopoietic Stem Cell Transplantation, Bone Marrow. Die Arbeit nennt 31 Literaturangaben. Gefördert von: The National Natural Science Foundation of China (NSFC) General Project, Research and Innovation Team Project for Scientific Breakthroughs at Shanxi Bethune Hospital, National High Technology Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic haematopoietic stem cell transplantation is a critical treatment for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), yet the risk of treatment failure still persists. Chimerism analysis serves as a potential tool for predicting disease recurrence and survival rates, but its specific role has not yet been clearly defined. This study aimed to explore the role of decreased T‐cell and bone marrow (BM) chimerism in predicting post‐transplant relapse and survival in patients with acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL). The study subjects were 305 AML and ALL patients who underwent allogeneic haematopoietic stem cell transplantation at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, from January 1, 2018, to September 1, 2023. We monitored the chimerism rate at monthly intervals after transplantation until either patient relapse or the end of follow‐up. T‐cell and BM chimerism were tested at the same time points. Relapse probabilities were estimated by the Kaplan–Meier method and compared with the log‐rank test. Gehan‐Breslow‐Wilcoxon test was used to assess the impact of T‐cell and BM chimerism levels on survival probabilities. In AML patients, our analysis revealed no significant correlation between the presence of initial mixed chimerism (at Day +30 post‐transplantation) and the relapse rate. Among patients with ALL, the number with initial mixed chimerism was insufficient for statistical analysis. In AML patients whose bone marrow chimerism rate decreased first ( n = 13) had a higher relapse rate and a lower survival rate than those whose T‐cell chimerism rate decreased first ( n = 11) ( p < 0.01). In patients with ALL, there was no significant difference in the relapse or survival rates between patients whose bone marrow chimerism rate decreased first ( n = 12) and those whose T‐cell chimerism rate decreased first ( n = 15) ( p > 0.05). While a decrease in bone marrow chimerism effectively predicts AML relapse, T‐cell chimerism demonstrates lower predictive efficacy. Further research is necessary to identify reliable predictors for relapse in ALL patients. The integration of chimerism analysis with other prognostic indicators, along with early monitoring and preemptive intervention, may enhance patient survival and quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteT-LymphocytesHematopoietic Stem Cell TransplantationBone MarrowPrecursor Cell Lymphoblastic Leukemia-LymphomaChimerismTransplantation ChimeraHumansAdultMaleFemaleRecurrenceAdolescentMiddle AgedTransplantation, HomologousYoung AdultChildPrognosisSurvival Rate

Stichwörter der Autor:innen

ALLAMLchimerism analysisrelapsesurvival

Autor:innen und Institutionen

  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • The Second Clinical College of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Hematology, Dongxihu District People's Hospital, Wuhan, Hubei, China.
  • Department of Psychietry, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei, China.
  • Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.

ORCID-Profile: Tongyuan Liu, Fankai Meng, Jia Wei, Lifang Huang

Förderung

  • The National Natural Science Foundation of China (NSFC) General Project
  • Research and Innovation Team Project for Scientific Breakthroughs at Shanxi Bethune Hospital
  • National High Technology Research and Development Program of China
  • National Research Center for Translational Medicine at Shanghai
  • Research Project of Hubei Provincial Health Commission
  • Shenzhen Science and Technology Program
  • National Natural Science Foundation of China

Zitieren

APA

Li, C., Liu, T., Wan, Y., Mao, H., Zhang, X., Meng, F., Wei, J., Zhang, Y., Chen, L., Jiang, L., & Huang, L. (2026). Comparative Analysis of T‐Cell and Bone Marrow Chimerism for Relapse Prediction in Acute Leukaemia Post‐Transplantation. HLA. https://doi.org/10.1111/tan.70588

Vancouver

Li C, Liu T, Wan Y, Mao H, Zhang X, Meng F, et al. Comparative Analysis of T‐Cell and Bone Marrow Chimerism for Relapse Prediction in Acute Leukaemia Post‐Transplantation. HLA. 2026. doi:10.1111/tan.70588

BibTeX
@article{Li2026,
  author = {Li, Chunfeng and Liu, Tongyuan and Wan, Ying and Mao, Hanwen and Zhang, Xiaofan and Meng, Fankai and Wei, Jia and Zhang, Yicheng and Chen, Liting and Jiang, Lijun and Huang, Lifang},
  title = {Comparative Analysis of T‐Cell and Bone Marrow Chimerism for Relapse Prediction in Acute Leukaemia Post‐Transplantation},
  journal = {HLA},
  year = {2026},
  doi = {10.1111/tan.70588}
}
Kostenlos starten →